Top Page
Trendlines Group
(SGX:42T)
Trendlines Group (42T) vs. iShares MSCI Singapore ETF (EWS)
Trendlines Group Business Overview & Revenue Model
Trendlines Group Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -8.32M | 1.72M | 4.50M | 3.58M | 2.30M | -3.76M |
| Gross Profit | -19.53M | -1.73M | -793.00K | -3.83M | -5.04M | -15.68M |
| EBITDA | -19.34M | -9.28M | -33.93M | -16.39M | 3.95M | -14.98M |
| Net Income | -18.87M | -9.43M | -33.99M | -14.48M | 6.56M | -4.93M |
Balance Sheet | ||||||
| Total Assets | 73.26M | 75.35M | 78.07M | 107.99M | 121.08M | 154.32M |
| Cash, Cash Equivalents and Short-Term Investments | 2.89M | 5.89M | 6.11M | 6.57M | 18.46M | 14.07M |
| Total Debt | 5.45M | 4.15M | 4.64M | 4.85M | 10.01M | 7.39M |
| Total Liabilities | 8.63M | 7.32M | 9.00M | 12.10M | 18.54M | 27.09M |
| Stockholders Equity | 65.47M | 68.55M | 70.89M | 96.99M | 103.09M | 127.21M |
Cash Flow | ||||||
| Free Cash Flow | -9.84M | -8.86M | -6.42M | -15.04M | 76.00K | -4.50M |
| Operating Cash Flow | -9.80M | -8.84M | -6.34M | -14.93M | 650.00K | -3.86M |
| Investing Cash Flow | -200.93K | -948.00K | 1.92M | 2.05M | -598.00K | -5.83M |
| Financing Cash Flow | 5.26M | 8.64M | 5.97M | 3.13M | 3.60M | -490.00K |
Trendlines Group Technical Analysis
Trendlines Group Peers Comparison
Trendlines Group Corporate Events
Trendlines has completed the previously announced transfer of management of its Trendlines Agrifood Fund Pte. Ltd. to Proterra Investment Advisors (Singapore) Pte. Ltd., after securing unanimous investor consent and fulfilling all regulatory and administrative requirements. Following the closing, Proterra becomes the sole investment manager, the fund will be renamed Proterra Trendlines Fund Pte. Ltd., and Trendlines Agrifood Innovation Centre Pte. Ltd. has stepped down from its investment manager role, a move the board says will sharpen Trendlines’ focus on its core activities while allowing the fund and its portfolio companies to leverage Proterra’s sector expertise and global network, and enabling Trendlines to continue benefiting from the fund’s performance under the new management structure.
The most recent analyst rating on (SG:42T) stock is a Hold with a S$0.07 price target. To see the full list of analyst forecasts on Trendlines Group stock, see the SG:42T Stock Forecast page.
Trendlines Group Ltd. has completed a private placement of 83,680,000 new ordinary shares at S$0.067 per share, increasing its issued and paid-up share capital from 1,371,813,553 to 1,455,493,553 shares. The new shares, representing about 5.75% of the enlarged share capital (excluding treasury shares), are fully paid, free of encumbrances, and will rank pari passu with existing shares except for dividends and distributions with record dates on or before completion, and are expected to commence trading on the Catalist board of the SGX-ST on 19 January 2026. This capital-raising exercise modestly dilutes existing shareholders but strengthens the company’s equity base, potentially enhancing its financial flexibility to pursue strategic initiatives and support its portfolio, while reinforcing its presence in Singapore’s growth-company market segment.
The most recent analyst rating on (SG:42T) stock is a Hold with a S$0.08 price target. To see the full list of analyst forecasts on Trendlines Group stock, see the SG:42T Stock Forecast page.
Trendlines Group has received in-principle approval from the Singapore Exchange (SGX-ST) for the listing and quotation of up to 83,680,000 new ordinary shares on the Catalist board at a placement price of S$0.067 per share, marking a key step in its proposed share placement. The placement shares must be allotted within seven market days from the approval date, positioning the company to raise fresh equity capital and potentially strengthen its balance sheet and funding capacity, though the exchange emphasizes that its approval does not indicate any view on the merits of the company or the offering, and Trendlines has indicated it will provide further updates to shareholders as the process advances.
The most recent analyst rating on (SG:42T) stock is a Hold with a S$0.08 price target. To see the full list of analyst forecasts on Trendlines Group stock, see the SG:42T Stock Forecast page.
Trendlines Group has launched a proposed private placement to raise S$5.6 million by issuing new shares representing roughly 5.75% of its enlarged share capital to a group of institutional and accredited investors, including clients managed by Lion Global Investors. The majority of the funds will be channelled into follow-on investments in selected portfolio companies, enabling Trendlines to maintain its stakes and capture more value as these businesses mature, a move that underscores confidence from new investors and supports the group’s strategy of achieving meaningful exits and long-term returns for shareholders.
The most recent analyst rating on (SG:42T) stock is a Hold with a S$0.08 price target. To see the full list of analyst forecasts on Trendlines Group stock, see the SG:42T Stock Forecast page.
Trendlines Group Ltd. has entered into a placement agreement with SAC Capital Private Limited, with Maybank Securities Pte. Ltd. acting as sub-placement agent, to place up to 83.68 million new ordinary shares at S$0.067 per share, raising up to S$5.61 million. The placement price represents a 9.03% discount to the previous trading day’s volume-weighted average price, and the new shares will account for about 6.10% of the current share capital (5.75% post-issue), be offered to institutional and accredited investors in Singapore via an exempt offering, and rank pari passu with existing shares except for entitlements declared before completion, implying a modest equity dilution as the company taps capital markets for additional funding.
The most recent analyst rating on (SG:42T) stock is a Hold with a S$0.08 price target. To see the full list of analyst forecasts on Trendlines Group stock, see the SG:42T Stock Forecast page.
Trendlines Group announced that its portfolio company Limaca Medical has signed an exclusive U.S. distribution agreement with a global leader in endoscopy equipment for Limaca’s Precision-GI™ automated biopsy system. The deal is expected to accelerate the nationwide clinical rollout and adoption of Precision-GI™, a motorized, EUS-guided biopsy device designed to obtain high-quality core tissue samples from pancreatic and other gastrointestinal lesions while reducing blood contamination. With existing FDA clearance, Breakthrough Device status and CMS Transitional Pass-Through payment, the partnership strengthens Limaca’s commercial positioning in GI cancer diagnostics and underscores Trendlines’ strategy of advancing innovative medtech assets that can improve diagnostic accuracy and access for patients with life‑threatening cancers.
The most recent analyst rating on (SG:42T) stock is a Hold with a S$0.08 price target. To see the full list of analyst forecasts on Trendlines Group stock, see the SG:42T Stock Forecast page.
The Trendlines Group Ltd. has appointed Ms. Lee Sock Wei as Joint Company Secretary with effect from 1 January 2026, joining existing Company Secretary Ms. Sahar Farah. The board-level corporate secretarial change underscores the company’s continued focus on strengthening its governance and compliance framework under the oversight of its Singapore sponsor, PrimePartners Corporate Finance, amid ongoing regulatory requirements for listed entities.
The most recent analyst rating on (SG:42T) stock is a Hold with a S$0.08 price target. To see the full list of analyst forecasts on Trendlines Group stock, see the SG:42T Stock Forecast page.
Trendlines Group Ltd., incorporated in Israel and listed on the Singapore Exchange Catalist board, has completed a share subscription exercise that bolsters its issued and paid-up share capital. The company allotted and issued 51,447,751 new ordinary shares at S$0.0666 per share, increasing its total share base from 1,320,365,802 to 1,371,813,553 shares, with the new shares ranking pari passu with existing shares and expected to begin trading on 2 January 2026; the board also corrected a clerical error in an earlier disclosure, clarifying that one subscriber, Ms Tan San-Ju, will receive 14,264,264 shares instead of 14,264,267, while confirming that all other details of the prior announcements remain unchanged.
The most recent analyst rating on (SG:42T) stock is a Hold with a S$0.08 price target. To see the full list of analyst forecasts on Trendlines Group stock, see the SG:42T Stock Forecast page.
Trendlines Group has received listing and quotation approval from the Singapore Exchange’s Catalist board for up to 51,447,751 new ordinary shares to be issued at S$0.0666 per share under a proposed subscription. The approval, which is conditional on the company meeting SGX listing requirements, paves the way for Trendlines to proceed with its planned share placement and potential equity fundraising, and the company has indicated it will provide further updates to shareholders as the transaction progresses.
The most recent analyst rating on (SG:42T) stock is a Hold with a S$0.08 price target. To see the full list of analyst forecasts on Trendlines Group stock, see the SG:42T Stock Forecast page.
Trendlines Group Ltd. has announced a management transfer agreement where Proterra Investment Advisors will become the sole investment manager of the Trendlines Agrifood Fund. This move aligns with Trendlines’ strategy to streamline operations and focus on core activities, leveraging Proterra’s expertise in private equity investments in the Asian food sectors. The agreement is expected to benefit the Fund’s portfolio companies and investors through Proterra’s extensive network and management capabilities.
The most recent analyst rating on (SG:42T) stock is a Hold with a S$0.08 price target. To see the full list of analyst forecasts on Trendlines Group stock, see the SG:42T Stock Forecast page.
Trendlines Group Ltd. has announced a subscription agreement for the issuance of up to 51,447,751 new ordinary shares at a price of S$0.0666 per share, totaling approximately S$3,426,420. This move, which is not underwritten and involves no placement agent, aims to raise capital through a group of individual subscribers introduced by a business contact, potentially impacting the company’s financial positioning and shareholder structure.
The most recent analyst rating on (SG:42T) stock is a Hold with a S$0.06 price target. To see the full list of analyst forecasts on Trendlines Group stock, see the SG:42T Stock Forecast page.
Trendlines Group Ltd. has announced several key developments, including the successful completion of a $10 million Series A funding round by its portfolio company, IBI Ag Ltd. Additionally, Trendlines is actively engaging with investors and the public through upcoming presentations at the SIAS Corporate Connect webinar and Sidoti’s Year End Virtual Investor Conference, showcasing its commitment to transparency and investor relations.
The most recent analyst rating on (SG:42T) stock is a Hold with a S$0.06 price target. To see the full list of analyst forecasts on Trendlines Group stock, see the SG:42T Stock Forecast page.
Trendlines Group’s portfolio company, IBI Ag, has successfully raised $10 million in a Series A funding round led by Corteva, marking a significant milestone in the development of its nanobody-based bioinsecticide platform. This investment will accelerate IBI Ag’s product development and regulatory milestones, advancing its biological pest control solutions towards commercialization, and highlights the potential of Trendlines’ investment model to foster disruptive innovation in the agrifood sector.
Trendlines Group Ltd. announced the departure of its Chief Financial Officer, Igor Vatenmacher, effective November 13, 2025, and highlighted recent investments in its portfolio companies. Notably, Celleste Bio Ltd. achieved a significant milestone by producing chocolate-grade cocoa butter using cell-cultured technology, and PregnanTech Ltd. was nominated for the 2025 MedTech World Awards in the FemTech Product of the Year category. These developments underscore Trendlines’ continued influence and innovation in the medical and agricultural technology sectors, potentially enhancing its market position and offering new opportunities for stakeholders.